Deutsche Bank AG cut its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,964,180 shares of the company

AMG National Trust Bank reduced its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 54.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,236 shares of the company

Beverly Hills Private Wealth LLC cut its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 59.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,600 shares of the company

Merck stock is riding fresh Phase 3 melanoma data for its personalized mRNA therapy intismeran combi

Merck & Co., Inc. (NYSE:MRK) jumped 12.6% to a record $152.20 on August 19 after a pivotal melanoma trial validated intismeran autogene, the individualized mRNA cancer therapy developed with Moderna. In the 1,137-patient Phase 3 INTerpath-001 study, intismeran plus Keytruda produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival compared with […]

Bellars Harris Wealth Management LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 79,847 shares of the company

ABN AMRO Bank N.V. reduced its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 7.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 136,228 shares of the company

Bank of New York Mellon Corp lowered its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,340,173 shares of the company

Merck & Co., Inc. (NYSE:MRK) Sets New 1-Year High Following Analyst Upgrade

Argus increased their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday.

Wolfe Research lifted their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an "outperform" rating in a research note on Tuesday.

Global Retirement Partners LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 78,760 shares of the company

Focus Partners Advisor Solutions LLC trimmed its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 11.9% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 86,089 shares of the company

Argent Trust Co boosted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 204,960 shares of the company